MBRX logo

Moleculin Biotech, Inc.


MBRX: Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.


Show MBRX Financials

Consumer Interest
SEC Filings

Recent trades of MBRX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by MBRX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of MBRX in WallStreetBets Daily Discussion


Recent insights relating to MBRX

CNBC Recommendations

Recent picks made for MBRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MBRX

Corporate Flights

Flights by private jets registered to MBRX